PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
- Author(s)
- Ali, LR; Garrido-Castro, AC; Lenehan, PJ; Bollenrucher, N; Stump, CT; Dougan, M; Goel, S; Shapiro, GI; Tolaney, SM; Dougan, SK;
- Details
- Publication Year 2023-04-03,Volume 220,Issue #4,Page e20220729
- Journal Title
- Journal of Experimental Medicine
- Publication Type
- Research article
- Abstract
- We performed single-cell RNA-sequencing and T cell receptor clonotype tracking of breast and ovarian cancer patients treated with the CDK4/6 inhibitor ribociclib and PD-1 blockade. We highlight evidence of two orthogonal treatment-associated phenomena: expansion of T cell effector populations and promotion of T cell memory formation. Augmentation of the antitumor memory pool by ribociclib boosts the efficacy of subsequent PD-1 blockade in mouse models of melanoma and breast cancer, pointing toward sequential therapy as a potentially safe and synergistic strategy in patients.
- Publisher
- Rockefeller University Press
- Keywords
- Animals; Mice; *Programmed Cell Death 1 Receptor; Aminopyridines/pharmacology; Purines; *Melanoma
- Department(s)
- Laboratory Research
- PubMed ID
- 36688919
- Publisher's Version
- https://doi.org/10.1084/jem.20220729
- Open Access at Publisher's Site
https://doi.org/10.1084/jem.20220729- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-07-18 07:52:26
Last Modified: 2023-07-18 07:52:55